Lynparza (Olaparib) Patent Expiration, LOE Window & CMS Spending

Lynparza (Olaparib) by AstraZeneca: FDA Orange Book core substance LOE 2027-09-08 (last listed 2041-10-25), 0 AB generics, $719.7M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAstraZeneca
FDA Application & PathwayN208558 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2027-09-08
Last Listed Patent or Exclusivity Date2041-10-25
Orange Book Patents (*PED Extensions)11 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$719.7M
2024 Medicare Part D Spend$593.9M
2024 Medicaid Spend$125.7M
Reported Wholesale Price Change (CA SB 17)8 WAC filings (max 16.6% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AstraZeneca across sibling Meru public-data platforms.